A TRIAL REFLECTIVE OF THE PATIENTS TYPICALLY SEEN IN YOUR PRACTICE
The first and only Phase III trial for 1L mPC based on a real-world population3
The multinational, randomized, Phase III MPACT study compared ABRAXANE + gemcitabine vs gemcitabine alone as first-line treatment in 861 patients with mPC with normal bilirubin and no prior chemotherapy in the metastatic setting. Primary endpoint was OS. ABRAXANE (125 mg/m2) + gemcitabine (1000 mg/m2) was given QW3/4. In the gemcitabine arm, gemcitabine (1000 mg/m2) was given QW7/8 then QW3/4.
- 1L=first-line; ECOG=Eastern Cooperative Oncology Group; KPS=Karnofsky Performance Status; MPACT=Metastatic Pancreatic Adenocarcinoma Clinical Trial; mPC=metastatic pancreatic cancer; OS=overall survival; PS=performance status.
- Conversion: KPS to ECOG PS
UNDERSTANDING THE RELATION BETWEEN
PERFORMANCE STATUS MEASUREMENTS5-7 UNDERSTANDING THE RELATION BETWEEN PERFORMANCE STATUS MEASUREMENTS5-7
This proposed conversion scale was constructed empirically from a sample of patients (n=1385) with advanced cancer, including different tumor types. Both KPS and ECOG PS were determined by 7 physicians for each patient. This conversion scale had the highest rate of agreement (75%) observed among all possible scales.7
- Patients Were Well Balanced Between Treatment Arms
PATIENTS WERE WELL BALANCED
BETWEEN TREATMENT ARMS3
- ULN=upper limit of normal.